Skip to main content
Professional Technical IVT

minimal/measurable residual disease

Also written as: MRD — Minimal/Measurable Residual Disease

Low levels of cancer cells remaining after treatment, detected by highly sensitive laboratory techniques.

Full Definition

Minimal residual disease (MRD), increasingly termed measurable residual disease, refers to the small number of cancer cells that remain in the body after treatment but are below the detection threshold of conventional morphologic assessment. Advanced techniques such as multiparameter flow cytometry, next-generation sequencing, and PCR-based assays can detect one malignant cell among 10,000 to 1,000,000 normal cells. MRD status has emerged as a powerful prognostic indicator and surrogate endpoint in clinical trials, influencing treatment duration decisions and transplantation timing. The terminology shift to 'measurable' reflects the quantitative nature of modern detection methods.

Usage

Usage note: Both 'minimal' and 'measurable' are acceptable; use consistently within documents

In Context

  • "MRD negativity after two cycles predicted superior progression-free survival in the clinical trial." — Clinical research manuscript
  • "The updated guidelines recommend MRD assessment using standardized flow cytometry protocols." — Clinical practice guideline

Also known as

MRD measurable residual disease

Contrasted with

complete remission undetectable disease

Don't confuse with

minimal disease microscopic disease

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON